A comprehensive review and meta-analysis of risk factors for statin-induced myopathy

Khoa A. Nguyen, Lang Li, Deshun Lu, Aida Yazdanparast, Lei Wang, Rolf Kreutz, Elizabeth C. Whipple, Titus Schleyer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To aid prescribers in assessing a patient’s risk for statin-induced myopathy (SIM), we performed a comprehensive review of currently known risk factors and calculated aggregated odds ratios for each risk factor through a meta-analysis. Methods: This meta-analysis was done through four phases: (1) Identification of the relevant primary literature; (2) abstract screening using inclusion and exclusion criteria; (3) detailed review and data extraction; and (4) synthesis and statistical analysis. Results: Out of 44 papers analyzed from 836 papers searched from MEDLINE, 18 different potential risk factors were collected, divided into three categories: three demographics (11 papers), ten clinical factors (31 papers), and five pharmacogenetics/biomarkers (12 papers). Risk factors significant for myopathy and/or rhabdomyolysis included age, gender, diabetes, renal impairment, cardiovascular disease, certain interacting drugs, and mutations of the SLCO1B1 gene, which encodes a transporter protein in the liver. Several factors, such as gender, race, cardiovascular disease, and the GATM gene, which encodes a protein for creatine synthesis, appeared to be protective in terms of the outcomes of interest. Conclusions: This comprehensive assessment of risk factors can help support clinicians in reducing the incidence of SIM in their patient population on statins.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalEuropean Journal of Clinical Pharmacology
DOIs
StateAccepted/In press - May 22 2018

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Muscular Diseases
Meta-Analysis
Cardiovascular Diseases
Rhabdomyolysis
Creatine
Pharmacogenetics
MEDLINE
Genes
Proteins
Biomarkers
Odds Ratio
Demography
Kidney
Mutation
Liver
Incidence
Pharmaceutical Preparations
Population

Keywords

  • Comprehensive review
  • Myotoxicity
  • Risk factors
  • Risks
  • Statin-induced myopathy
  • Statins

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. / Nguyen, Khoa A.; Li, Lang; Lu, Deshun; Yazdanparast, Aida; Wang, Lei; Kreutz, Rolf; Whipple, Elizabeth C.; Schleyer, Titus.

In: European Journal of Clinical Pharmacology, 22.05.2018, p. 1-11.

Research output: Contribution to journalArticle

Nguyen, Khoa A. ; Li, Lang ; Lu, Deshun ; Yazdanparast, Aida ; Wang, Lei ; Kreutz, Rolf ; Whipple, Elizabeth C. ; Schleyer, Titus. / A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. In: European Journal of Clinical Pharmacology. 2018 ; pp. 1-11.
@article{fb84b0b27b4043ba917eb3396aacce36,
title = "A comprehensive review and meta-analysis of risk factors for statin-induced myopathy",
abstract = "Purpose: To aid prescribers in assessing a patient’s risk for statin-induced myopathy (SIM), we performed a comprehensive review of currently known risk factors and calculated aggregated odds ratios for each risk factor through a meta-analysis. Methods: This meta-analysis was done through four phases: (1) Identification of the relevant primary literature; (2) abstract screening using inclusion and exclusion criteria; (3) detailed review and data extraction; and (4) synthesis and statistical analysis. Results: Out of 44 papers analyzed from 836 papers searched from MEDLINE, 18 different potential risk factors were collected, divided into three categories: three demographics (11 papers), ten clinical factors (31 papers), and five pharmacogenetics/biomarkers (12 papers). Risk factors significant for myopathy and/or rhabdomyolysis included age, gender, diabetes, renal impairment, cardiovascular disease, certain interacting drugs, and mutations of the SLCO1B1 gene, which encodes a transporter protein in the liver. Several factors, such as gender, race, cardiovascular disease, and the GATM gene, which encodes a protein for creatine synthesis, appeared to be protective in terms of the outcomes of interest. Conclusions: This comprehensive assessment of risk factors can help support clinicians in reducing the incidence of SIM in their patient population on statins.",
keywords = "Comprehensive review, Myotoxicity, Risk factors, Risks, Statin-induced myopathy, Statins",
author = "Nguyen, {Khoa A.} and Lang Li and Deshun Lu and Aida Yazdanparast and Lei Wang and Rolf Kreutz and Whipple, {Elizabeth C.} and Titus Schleyer",
year = "2018",
month = "5",
day = "22",
doi = "10.1007/s00228-018-2482-9",
language = "English (US)",
pages = "1--11",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - A comprehensive review and meta-analysis of risk factors for statin-induced myopathy

AU - Nguyen, Khoa A.

AU - Li, Lang

AU - Lu, Deshun

AU - Yazdanparast, Aida

AU - Wang, Lei

AU - Kreutz, Rolf

AU - Whipple, Elizabeth C.

AU - Schleyer, Titus

PY - 2018/5/22

Y1 - 2018/5/22

N2 - Purpose: To aid prescribers in assessing a patient’s risk for statin-induced myopathy (SIM), we performed a comprehensive review of currently known risk factors and calculated aggregated odds ratios for each risk factor through a meta-analysis. Methods: This meta-analysis was done through four phases: (1) Identification of the relevant primary literature; (2) abstract screening using inclusion and exclusion criteria; (3) detailed review and data extraction; and (4) synthesis and statistical analysis. Results: Out of 44 papers analyzed from 836 papers searched from MEDLINE, 18 different potential risk factors were collected, divided into three categories: three demographics (11 papers), ten clinical factors (31 papers), and five pharmacogenetics/biomarkers (12 papers). Risk factors significant for myopathy and/or rhabdomyolysis included age, gender, diabetes, renal impairment, cardiovascular disease, certain interacting drugs, and mutations of the SLCO1B1 gene, which encodes a transporter protein in the liver. Several factors, such as gender, race, cardiovascular disease, and the GATM gene, which encodes a protein for creatine synthesis, appeared to be protective in terms of the outcomes of interest. Conclusions: This comprehensive assessment of risk factors can help support clinicians in reducing the incidence of SIM in their patient population on statins.

AB - Purpose: To aid prescribers in assessing a patient’s risk for statin-induced myopathy (SIM), we performed a comprehensive review of currently known risk factors and calculated aggregated odds ratios for each risk factor through a meta-analysis. Methods: This meta-analysis was done through four phases: (1) Identification of the relevant primary literature; (2) abstract screening using inclusion and exclusion criteria; (3) detailed review and data extraction; and (4) synthesis and statistical analysis. Results: Out of 44 papers analyzed from 836 papers searched from MEDLINE, 18 different potential risk factors were collected, divided into three categories: three demographics (11 papers), ten clinical factors (31 papers), and five pharmacogenetics/biomarkers (12 papers). Risk factors significant for myopathy and/or rhabdomyolysis included age, gender, diabetes, renal impairment, cardiovascular disease, certain interacting drugs, and mutations of the SLCO1B1 gene, which encodes a transporter protein in the liver. Several factors, such as gender, race, cardiovascular disease, and the GATM gene, which encodes a protein for creatine synthesis, appeared to be protective in terms of the outcomes of interest. Conclusions: This comprehensive assessment of risk factors can help support clinicians in reducing the incidence of SIM in their patient population on statins.

KW - Comprehensive review

KW - Myotoxicity

KW - Risk factors

KW - Risks

KW - Statin-induced myopathy

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=85047186530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047186530&partnerID=8YFLogxK

U2 - 10.1007/s00228-018-2482-9

DO - 10.1007/s00228-018-2482-9

M3 - Article

C2 - 29785580

AN - SCOPUS:85047186530

SP - 1

EP - 11

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

ER -